Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type

Mahdi Al Dhafiri; Flore Sicre de Fontbrune; Eduardo Marinho; Lydia Deschamps; Julie Di-Lucca; Beatrice Crickx; Vincent Descamps

doi:10.1002/ccr3.2137

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type

Clin Case Rep. 2019 Apr 5;7(5):964-967. doi: 10.1002/ccr3.2137. eCollection 2019 May.

Authors

Mahdi Al Dhafiri^{1

2}, Flore Sicre de Fontbrune³, Eduardo Marinho⁴, Lydia Deschamps⁴, Julie Di-Lucca⁵, Beatrice Crickx¹, Vincent Descamps¹

Affiliations

¹ Department of Dermatology Bichat Hospital Paris France.
² Department of Dermatology, College of Medicine King Faisal University Al-Ahsa Saudi Arabia.
³ Department of Hematology Saint-Louis Hospital Paris France.
⁴ Department of Anatomopathology Bichat Hospital Paris France.
⁵ Department of Dermatology Lausanne University Hospital Lausanne Switzerland.

Abstract

The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.

Keywords: chemotherapy; leg type; lenalidomide; primary cutaneous diffuse large B‐cell lymphoma.

Publication types

Case Reports